Cargando…
Combination chemotherapy of valproic acid (VPA) and gemcitabine regulates STAT3/Bmi1 pathway to differentially potentiate the motility of pancreatic cancer cells
BACKGROUND: Gemcitabine is the standard first-line chemotherapy regimen for pancreatic cancer. However, its therapeutic value is substantially limited in pancreatic cancer patients due to occurrence of resistance towards gemcitabine. A strategy of combined chemo-regimens is widely employed in clinic...
Autores principales: | Li, Hehe, Zhang, Zhengle, Gao, Chenggang, Wu, Shihong, Duan, Qingke, Wu, Heshui, Wang, Chunyou, Shen, Qiang, Yin, Tao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6582499/ https://www.ncbi.nlm.nih.gov/pubmed/31244991 http://dx.doi.org/10.1186/s13578-019-0312-0 |
Ejemplares similares
-
Correction: Combination chemotherapy of valproic acid (VPA) and gemcitabine regulates STAT3/Bmi1 pathway to differentially potentiate the motility of pancreatic cancer cells
por: Li, Hehe, et al.
Publicado: (2023) -
Up‐regulation of glycolysis promotes the stemness and EMT phenotypes in gemcitabine‐resistant pancreatic cancer cells
por: Zhao, Hengqiang, et al.
Publicado: (2017) -
ROS/KRAS/AMPK Signaling Contributes to Gemcitabine-Induced Stem-like Cell Properties in Pancreatic Cancer
por: Zhao, Hengqiang, et al.
Publicado: (2019) -
High glucose promotes pancreatic cancer cells to escape from immune surveillance via AMPK-Bmi1-GATA2-MICA/B pathway
por: Duan, Qingke, et al.
Publicado: (2019) -
Mechanistic Evaluation and Translational Signature of Gemcitabine-induced Chemoresistance by Quantitative Phosphoproteomics Analysis with iTRAQ Labeling Mass Spectrometry
por: Duan, Qingke, et al.
Publicado: (2017)